The Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality ...

Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030Ramat Gan, Israel, Feb. 18, 2025 (GLOBE ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.08. Operator: Good morning, ladies and gentlemen, and welcome to ...

JENA, Germany - InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company focusing on anti-inflammatory therapeutics, has initiated a public offering of its ordinary shares along with pre-funded ...

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

Millions of South Africa are suffering with symptoms generally known as Long Covid. This growing crisis is shattering lives, ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

When you have Covid, there’s a phase when the virus is quickly replicating, followed by an inflammatory response phase when your body fights off the virus, explained Dr. Mahdee Sobhanie ...

People with immune system health problems continue to take precautions against COVID-19 five years into the pandemic.

Preclinical studies have shown their potential to reduce inflammation and modulate immune responses in diseases like rheumatoid arthritis and lupus.